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The protective effect of dexamethasone and lactate against
cisplatin-induced ototoxicity*
Arif ŞANLI1, Sedat AYDIN1, Zeynep Alev SARISOY2, Mustafa PAKSOY1, Emin AYDURAN3,
4

Özlem ÇELEBİ ERDİVANLI

Aim: To compare the protective effect of dexamethasone and lactate against cisplatin-induced ototoxicity.
Materials and methods: Thirty Wistar rats were randomly divided into 4 groups. After the rats were sedated with
intraperitoneal (IP) ketamine hydrochloride (50 mg/kg) and xylazine (7.5 mg/kg), baseline ABRs (auditory brainstem
evoked responses) were measured in response to clicks and tone pips of 4, 8, 12, and 16 kHz. After auditory thresholds
were determined, the animals received drug administration as follows: Group 1 (n: 6) received intratympanic (IT)
saline (0.9% NaCl) solution, Group 2 (n: 8) IP cisplatin (20 mg/kg) alone, Group 3 (n: 8) IT dexamethasone (0.1-0.3
mL), and Group 4 (n: 8) IT lactated Ringer’s (LR) solution (0.1-0.3 mL) followed after 30 min by 20 mg/kg cisplatin.
Dexamethasone, LR solution, and saline application were continued for 3 days. At the end of the study, ABR testing was
performed and threshold changes were recorded.
Results: Group 2 animals showed marked hearing loss with average threshold shifts of 39,6 dB for clicks, 7.2 dB at 4
kHz, 8.4 dB at 8 kHz, 71.1 dB at 12 kHz and 71.8 dB at 16 kHz. No significant loss was observed in Group 3 with average
threshold shifts of 1.6 dB, 4.7 dB, 8.7 dB, and 4.2 dB for clicks and tone pips at 4, 8, 12, and 16 kHz, respectively. Similar
findings were observed in Group 4 with shifts of 3.5 dB, 6.8 dB, 11.3 dB, and 15.2 dB for clicks and tone pips at 4, 8, 12,
and 16 kHz, respectively. Significant protection was seen in Group 3 and 4 animals compared with Group 2 animals.
There was no side effect in IT administration of LR solution and dexamethasone for hearing functions. Both of these
appear to be easier and safer to apply and have a usable protective effect against cisplatin ototoxicity.
Conclusion: IT administration of LR solution and dexamethasone appear to be easy and safe to apply and have a useful
protective effect. Clinical applications including these agents could be considered for use in order to reduce the side
effects of ototoxic chemotherapy protocols.
Key words: Cisplatin, ototoxicity, dexamethasone, lactated ringer’s solution, otoprotection, rat, intratympanic route

Sisplatin ototoksisitesinde dekzametazon ve laktat’ın koruyucu etkinliği
Amaç: Sisplatin ototoksisitesinde intratimpanik deksametazon ve laktatın koruyucu etkinlikleri karşılaştırıldı.
Yöntem ve gereç: Otuz Wistar cinsi sıçan rastgele dört guruba ayrıldı. Sıçanlar intraperitonal ketamine hydrochloride
(50 mg/kg) ve xylazine (7.5 mg/kg) ile sedatize edildikten sonra, Bütün hayvanların uygulamalar öncesinde ABR
(Auditory brainstem response) ile 4, 8, 12 ve 16 kHz’de klik ve “tone-pips” uyaranlarla bazal işitme eşikleri saptandı.
Oditör eşikler saptandıktan sonra, sıçanlara aşağıdaki sırayla ilaçlar uygulandı: 1. Grup (n: 6) intratimpanik % 0,9 salin
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(NaCl) solusyonu; 2. Grup (n: 8), yalnızca intraperitoneal sisplatin (20 mg/kg); 3. Grup (n: 8) intraperitoneal sisplatin
ile birlikte intratimpanik dekzametazon (0.1-0.3 mL) ve 4. Grup (n: 8) 20 mg/kg sisplatin uygulamasından 30 dakika
sonra intratimpanik Ringer laktat (RL) solusyonu (0.1-0.3 mL) uygulandı Dekzametazon, RL solusyonu ve % 0,9 salin
uygulamasına üç gün boyunca devam edildi. Çalışmanın sonunda, ABR testi uygulandı ve eşik değişimleri ölçüldü.
Bulgular: 2. Grup taki sıçanlar uygulama öncesi ve sonrası işitme eşikleri arası ortalama fark 39,6 dB olup 4 kHz de
7,2 dB, 8 kHz de 8,4 dB,12 kHz de 71,1 dB ve 16 kHz de 71,8 dB lik eşik farkları saptandı. 3. grupta belirgin işitme kaybı
gözlenmedi. Klik ve “tone-pips” uyaranlara karşı işitme eşikleri arası ortalama fark 4, 8, 12 ve 16 kHz frekansları için
sırasıyla 1,60 dB, 4,75 dB, 8,70 dB, ve 4,26 dB olarak ölçüldü. Benzer bulgular 4. gruptada saptandı. Bu grupta klik ve
“tone-pips” uyaranlara karşı işitme eşikleri arası ortalama fark 4, 8, 12 ve 16 kHz frekansları için sırasıyla 3,56 dB, 6,87
dB, 11,34 dB, ve 15,29 dB olarak ölçüldü. 2. gruba kıyasla 3. ve 4. grup sıçanlarda belirgin olarak işitmenin korunduğu
saptandı. Ayrıca işitme fonksiyonları üzerine intratimpanik RL ve dekzametazonun herhangi bir yan etkisinin olmadığı
ve bu iki ajanın sisplatin ototoksisitesinde kolay uygulanabilir, güvenli ve koruyucu olduklarını söyleyebiliriz.
Sonuç: İntratimpanik RL solusyonu ve dekzametazon kolay uygulanabilen ve güvenli ajanlardır. kemoterapi
protokollerinin ototoksik yan etkilerini azaltmak için klinik uygulamalara bu ajanların dahil edilmesi uygun olacaktır.
Anahtar sözcükler: Cisplatin, ototoksisite, dekzametazon, ringer laktat solusyonu, sıçan, intratimpanik yöntem

Introduction
Cisplatin is an effective antineoplastic agent
widely used in medullablastoma, neuroblastoma,
osteosarcoma, and various cancer treatments
(testicular, ovarian, cervix, bladder, lung, and brain)
(1). However, there are various side effects related to
non-specific cytotoxic influences. A common dose
side effect is ototoxicity (2). Cisplatin ototoxicity in
adults and children may lead to hearing loss starting
as sensorineural tinnitus. Hearing loss begins at
high frequencies and then progresses towards lower
frequencies, which are crucial for hearing speech
(2-4). The resultant hearing loss depends on the
dose. Hearing loss may be cumulative, bilateral, and
permanent. Some 60% to 80% of patients experience
some hearing loss and approximately 15% experience
permanent hearing loss (5,6). Cisplatin provides
development reactive oxygen species (ROT) as
superoxide anions at a molecular level. Glutathione
and antioxidant enzymes are released as ROT rise.
In this case, superoxide hydrogen peroxide and
toxic lipids cause apoptosis with calcium entrance to
cochlear cells (7-9). Many experimental studies have
been done to find the most suitable otoprotective
agent mostly as an antioxidant supplement against
ROT at early stages of ototoxicity (10). Unfortunately,
most of these agents inhibit antitumoral effects of
cisplatin (1). As a result, there are no clinical agents
that prevent cisplatin ototoxicity at present.
Glucocorticoids (GCs) are used in hearing loss
treatment for various cochlear diseases when the
etiology is not clear as in otoimmune inner ear
468

disorder, endolymphatic hydrops, Méniere’s disease,
tinnitus, and sudden or idiopathic rapidly progressing
hearing loss (11). It has been shown that the existence
of GCs receptors in the rat’s inner ear structure is
effective in limiting steroid ROT development (1214). The protective effect of lactated Ringer’s (LR)
solution is not known yet. However, it is thought
that LR solution is effective via nicotinamide adenine
dinucleotide (NADH). Lactate dehydrogenase H
isoenzyme (LDH-H), which is the originator of the
endogenic antioxidant NADH converts lactate into
pyruvate.
It has been shown that cisplatin doses do not cause
LDH inhibition in clinical or experimental studies.
At the same time, perilymph concentrations of LDH
and lactate are found 3 times more than those of
blood or cerebrospinal fluid (15,16).
One of the aims of the experiment described
herein was to identify a laboratory animal that would
be ototoxically susceptible and consequently would
have the potential to be used as a model in the study
of early effects of cisplatin on auditory function. For
this purpose, we used Wistar rats as an animal model
to determine the ototoxicity of cisplatin. Cisplatin was
systemically administered with 2 high doses to rats,
and the ototoxic effects were evaluated. If ototoxicity
occurs, it can be prevented by IT administration
of dexamethasone or LR solution. In addition, this
study investigated the role of auditory brainstem
evoked response (ABR) as an indicator of cisplatininduced ototoxicity and ABR thresholds were used to
compare the ototoxicity in these animals.
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Materials and methods
This study was approved by the Committee
for Ethics in Animal Experiments of the Current
Haydarpaşa Numune Training and Research Hospital
with protocol number (13/2009). Thirty healthy
Wistar rats (190-300 g) were housed in temperature
controlled rooms with 12-h light/dark cycles. These
animals were provided with free access to food and
water. They were allowed to acclimatize to their cages
for at least 48 h after shipment. They were sedated
using an intraperitoneal (IP) solution of 50 mg/kg
ketamine hydrochloride (Ketalar, Eczacıbaşı, Turkey)
and 7.5 mg/kg xylazine (Rompun, Bayer, Germany).
Rectal temperatures were continuously monitored
while the animals were under anesthesia. The animals
were also placed on a warming blanket calibrated to
maintain body temperature at 35 °C. The rats were
divided into 4 study groups after baseline ABR testing
was performed (Table 1). All tympanic membranes
were examined with an operating microscope (Zeiss,
S1, Germany) before earphone placement to ensure
normal middle ear appearance.
Group 1: (6 rats, 12 ears) Saline (0.9% NaCl)
solution was selected as the control agent because it is
the solvent in which dexamethasone was stored and
administered for 3 days.
Group 2: (8 rats, 16 ears) cisplatin 20 mg/kg was
given as an IP infusion (Cisplatin-teva 10 mg 1
flakon, Med-ilac, İstanbul, Turkey) for 2 days.
Group 3: (8 rats, 16 ears) cisplatin 20 mg/kg was
given IP as a slow infusion and rats received 4 mg/
kg IT dexamethasone (Onadron flakon, I.E. Ulagay,
İstanbul, Turkey), followed after 30 min and 24 h by
an IP infusion of cisplatin. This was administered

under an operating microscope, slowly through a
myringotomy in the anterosuperior quadrant, with a
28-gauge dental needle to fill the middle ear cavity
(approximately 0.1 to 0.3 mL). After keeping the
animal in the same position for 30 min, the procedure
was performed in the other ear.
Group 4: (8 rats, 16 ears) received intratympanic
(IT) LR solution (lactate, 28 mEq/L) (approximately
0.1 to 0.3 mL) (Eczacıbaşı-Baxter, İstanbul, Turkey),
followed after 30 min and 24 h by IP cisplatin.
After an observation period of 3 days, the animals
were again sedated and follow-up ABR testing was
performed to determine the degree of threshold
change compared with baseline measures. No
tympanic membrane perforations or complications
were observed as a result of these procedures.
Auditory brainstem evoked responses testing
A total of 30 rats were used for ABR recording.
Rats were sedated with xylazine and ketamine.
Baseline ABRs were measured using the Smart EP
evoked potential system (Intelligent Hearing Systems,
Miami, FL, USA). Responses to 100 μs clicks and
tone pips with an 8-ms plateau and a 1-ms rise fall
time at 4, 8, 12, and 16 kHz were averaged using this
instruments signal generating averaging system. The
stimuli were presented inside a double-walled radio
frequency-shielded sound booth using an Etymotic
ER-2 earphone placed directly into the ear canal.
Clicks and tone pips were presented at a rate of 5 times
per second. Animals were presented with a stimulus
intensity series, which began at 10 dB sound pressure
level (SPL) and reached a maximum of 90 dB SPL.
Stimulus intensity was progressively increased in 10
dB increments. Resulting ABRs were observed on a

Table 1. Distribution of rats and application numbers according to study groups.
The rats
(n)

Applications
(n)

Negative control with IT injection

6

3

IP. cisplatin

Ototoxicity group

8

2

3

IP. cisplatin with IT.dexamethasone

Treatment group

8

5

4

IP. cisplatin with IT. lactate

Treatment group

8

5

Groups

Used procedure

Description

1

IT. saline solution

2
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video monitor. Intensities that appeared to be near
threshold were repeated. Threshold was defined as
the lowest intensity capable of producing a visually
detectable, reproducible response. The voltage
associated with threshold was 0.5 μV. Subdermal
electrodes were used to record brain potentials
differentially. The active electrode was positioned at
the vertex and the reference electrode at the mastoid
tip contralaterally. The ground electrode was located
over the mastoid tip ipsilaterally. Potentials were
amplified 1000 times inside the sound attenuation
booth (bandwith 0.1-10 kHz), and signals were
further amplified to produce an overall gain of
nearly 100,000 and viewed on an oscilloscope. The
ABR were sampled for 20.5 ms after stimulus onset.
Stimuli were repeated 5 times per second, and a total
of 512 trials were averaged using an analog to digital
converting system. After an observation period of 3
days, the animals were again sedated, and underwent
follow-up ABR testing to determine the degree of
threshold change from baseline.
Statistical analysis
NCSS 2007 & PASS 2008 Statistical Software
(Utah, USA) was used. This software suggested
that a sample size of 30 animals would be sufficient
for statistical significance. Considering possible
unforeseen events resulting in the loss of animals
during the study, we used 30 animals in 4 groups of
6, 8, 8, 8, i.e. 30 animals were randomly assigned to

4 groups, each group including 16 ears, except the
control group. The data were analyzed using the
Wilcoxon paired 2-sample test, Mann-Whitney U
test, and Kruskal-Wallis variance analysis in SPSS
11.0 for Windows. A P value of less than or equal to
0.05 was considered significant.
Results
ABR threshold shifts for clicks were compared
following drug administration; the results are shown
in Table 2. No significant change in hearing was
seen in animals receiving saline (Group 1) with
shifts of 1.1 dB, 1.4 dB, 2.5 dB, and 3.3 dB for clicks
at 4, 8, 12, and 16 kHz, respectively. There were no
significant differences in the ABR thresholds (P >
0.05) after administration of saline. The injections
had no toxic effect on cochlear emissions in any of
the rats. Marked hearing loss was noted in animals
receiving cisplatin (Group 2) with average threshold
shifts of 39.6 dB for all frequencies, 7 dB at 4 kHz,
8 dB at 8 kHz, 7 dB at 12 kHz, and 7 dB at 16 kHz.
Differences in ABR thresholds at frequencies 4 to 8
kHz were not statistically significant (4 kHz P = 0.17,
8 kHz P = 0.08). However, ABR thresholds decreased
significantly at frequencies 12 to 16 kHz 3 days after IP
cisplatin injection (12 kHz P = 0.003, 16 kHz P = 0.003)
(Figure). A significant degree of otoprotection was
observed in Group 3 animals with average threshold

Table 2. Mean hearing levels (dB) before (pre) and after (post) drug administration.
Group 1

Group 2

Group 3

Group 4

dB

dB

dB

dB

Pre

12

16

23

23

Post

13

23

24

26

Pre

10

13

12

21

Post

11

22

17

28

Pre

31

15

34

37

Post

33

86

43

48

Pre

28

16

32

32

Post

31

88

36

48

Hearing frequencies

4 kHz

8 kHz

12 kHz

16 kHz
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0

4 kHz pre 8 kHz pre 12 kHz pre 16 kHz pre

4 kHz post 8 kHz post

12 kHz
post

16 kHz
post

10
20
30
40
50
60
70
80

saline
cisplatin
cisp+dexa
cisp+lactate

90
100

Figure. Mean hearing levels (dB) before (pre) and after (post) drug administration.

for squamous cell carcinoma of the head and neck.
However, it is an antineoplastic agent with an
ototoxic side effect. Factors affecting the incidence
of ototoxicity are application route, cumulative dose,
age, dietary factors, plasma protein level, genetic
factors, and cranial radiotherapy history. The ototoxic
effect usually appears on the 2nd day of treatment
and may continue up to 7 days after treatment (1-4).

shifts of 4.8 dB for all frequencies, 1 dB for 4 kHz, 4
dB for 8 kHz, 8 dB for 12 kHz, and 4 dB for 16 kHz.
Moreover, a significant degree of otoprotection was
observed in Group 4 animals with average threshold
shifts of 9.2 dB for all frequencies, 3 dB for 4 kHz, 6
dB for 8 kHz, 11 dB for 12 kHz, and 15 dB for 16 kHz
(Table 3). In Group 3 as well as in Group 4, there were
no significant differences in ABR thresholds before
and after administration of IT dexamethasone or RL
solution (P > 0.05) suggesting that IT dexamethasone
or RL solution had an otoprotective effect in subjects
given 2 high doses of cisplatin (P < 0.01).

The ototoxicity of cisplatin first appears
histopathologically on the first row of cells on the
curve of the cochlea then moves upwards towards the
outer hair cells and damages inner hair cells together
with the organ of corti, spiral ganglion, and stria
vascularis (10,17-19). Nitric oxide (NO) occurrence
is blamed for the ototoxicity of cisplatin, which is
a result of excessive production of ROT and nitric
oxide synthase (NOS) (20).

Discussion
Cisplatin is now the most widely used anticancer
drug for a variety of human neoplasms especially

Table 3. The hearing loss average shift levels (dB) before and after drug application.
Group 1

Group 2

Group 3

Group 4

dB

dB

dB

dB

4 kHz

1.10

7.25

1.60

3.56

8 kHz

1.45

8.44

4.75

6.87

12 kHz

2.55

71.12

8.70

11.34

16 kHz

3.35

4.26

15.29

Frequencies

71.83
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Many studies have been conducted concerning the
ototoxicity of cisplatin. Clinical studies done in the
last 8-10 years have shown that L- and D-methionine,
sodium thiosulfate, ebselen, and 4-methyl thiobenzoic
acid are significant effective agents (21-27). These
agents are used locally or systemically. Reduction of
cisplatin anti-tumor activity is observed in animal
studies during the course of systemic antioxidant
application except for ebselen (27). Animal studies
have shown that GCs reduce NO related harm
on cochlear cells in ototoxicity of cisplatin and
aminoglycoside ototoxicity, which are estimated
to have similar pathogenesis and protective effects
as well as inhibiting release of reactive nitrogen
mediator (14,28). In this respect, GCs are used as
IT as a current method in local inner ear treatment.
Diffusion to the inner ear spreads through the round
window membrane. In this manner, GCs can provide
a higher concentration in the inner ear compared
to other oral or parenteral routes. It was found that
an IT injection of methylprednisolone produced
perilymph concentrations that were 33-fold higher
and plasma concentrations that were 136-fold lower
than the respective concentrations from parenteral
dosing (29). Separately local administration prevents
systemic absorption, avoiding the common systemic
side effects of steroids including hyperglycemia,
peptic ulcers, hypertension, osteoporosis, and more
problematic reduced efficacy of chemotherapeutic
agents (11,14).
GCs have been used to safely and widely treat other
inner ear disorders such as sudden sensorineural
hearing loss and Méniere’s disease for several years
(11). Daldal (28) and Hill et al. (30) demonstrated
the protective effect of IT dexamethasone against
cisplatin-induced ototoxicity in guinea pigs and IT
dexamethasone had no ototoxic or systemic side
effects on DPOAE measurements. The present study
suggests that dexamethasone does not have a side
effect on cochlear function, and the findings concur
with those of recent studies.
We hypothesize that IT dexamethasone may also
have a place for preventing cisplatin ototoxicity. We
used local application to exclude possible adverse
effects of systemic application and to achieve a higher
concentration of dexamethasone in the cochlear
fluid more rapidly. Only 0.1 to 0.3 mL was enough to
472

cover the round window, although sampling from the
inner ear for the measurement of the diffused drug
concentration was not done. In the present study,
there were no significant differences in the pre- and
post-drug injection measurements of ABR threshold
shifts to the click in Group 3.
Even though lactate’s protective action is not
clearly explained yet, current evidence shows that
cisplatin and lactate (in the form of LR solution) may
have important effects on outer hair cell metabolism,
both revolving around the depletion and repletion
of intracellular NADH, which is an endogenous
antioxidant. Of the other components of LR solution,
lactate is the most likely to provide the protective
role. All of the other components have been found
to have either equivocal or potentiating effects on
cisplatin ototoxicity (15). In a study of protectivity of
LR solution and N-acetlysystein, these 2 substances
are given by IT method to guinea pigs simultaneously
after creating cisplatin ototoxicity. The N-acetlysystein
applied group demonstrated mid-grade improvement
in their hearing level but the LR solution applied group
demonstrated nearly full improvement. This study
explains that the reason for lactate’s otoprotective
effect being higher is the lower molecular weight
of lactate compared with N-acetlysystein, allowing
it to pass through the round window membrane
more easily (15). We also found that there were
no statistically significant differences in hearing
threshold shifts after administration of cisplatin in
the LR solution applied group. In the present study,
there were no significant differences in the pre- and
post-drug injection measurements of ABR threshold
shifts for the click in Group 3, but we observed that
the dexamethasone applied group demonstrated more
improvement in their hearing level compared to the
LR solution applied group (P > 0.05).
In the present study no differences were found
in the average ABR thresholds for Groups 1, 3, and
4 before and after application. However, significant
differences were observed especially at 12 and 16
kHz for Group 2, which indicates the side effect of
cisplatin’s ototoxicity. The present study demonstrated
a smaller hearing loss after application of cisplatin
for Groups 3 and 4 related to dexamethasone and
LR solution having a protective effect over cisplatin’s
ototoxicity. Our findings support a few articles in the
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literature written about this issue. Moreover, we used
ABR testing, which measures threshold, as opposed
to using otoacoustic emissions.
In our study we used dexamethasone and LR
solution because there was no research comparing the
effectiveness of these 2 agents in relation to cisplatin’s

ototoxicity. There have been concerns about IT
treatment in recent years. Knowledge gained from
this kind of experimental application with several
agents could be readily transferred into clinical
practice to increase the safety of cancer treatments
in the future.
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